Overview: SURMOUNT Programme Dosing Design
Tirzepatide's clinical dosing framework was established across the four completed SURMOUNT trials. SURMOUNT-1, published in the New England Journal of Medicine in 2022 (doi:10.1056/NEJMoa2206038), enrolled 2,539 adults without type 2 diabetes and compared weekly subcutaneous Tirzepatide at 5mg, 10mg, and 15mg against placebo over 72 weeks. The 15mg cohort achieved the landmark mean body weight reduction of 20.9% from baseline.
All cohorts used a 2.5mg initiation dose and a stepwise escalation — the primary design principle being tolerability management. Tirzepatide's dual GLP-1/GIP receptor agonism produces a stronger gastrointestinal adverse event signal than single-receptor agents at comparable efficacy doses, making the gradual escalation approach particularly important. The 2.5mg starting dose is pharmacologically sub-therapeutic for weight outcomes but allows GI adaptation before reaching the active dose range.
This article summarises the published SURMOUNT trial dosing protocols as a reference for researchers. Tirzepatide supplied by RetaLABS is for laboratory research use only — not for human consumption.
SURMOUNT-1 Dose Escalation Schedules
Three active cohorts used different maintenance targets, each reached via stepped escalation with 4-week intervals:
| Weeks | 5mg Cohort | 10mg Cohort | 15mg Cohort |
|---|---|---|---|
| 1–4 | 2.5 mg | 2.5 mg | 2.5 mg |
| 5–8 | 5 mg (maintenance) | 5 mg | 5 mg |
| 9–12 | — | 7.5 mg | 7.5 mg |
| 13–16 | — | 10 mg (maintenance) | 10 mg |
| 17–20 | — | — | 12.5 mg |
| 21–72 | — | — | 15 mg (maintenance) |
The protocol allowed dose reduction (not escalation pause) if tolerability was insufficient — a participant unable to tolerate 15mg could reduce to 10mg rather than discontinue. This design detail is relevant to researchers: dose flexibility within the escalation range is consistent with published protocol and does not invalidate a research timeline.
Reconstitution Calculations for 30mg Lyophilised Vials
RetaLABS Tirzepatide is supplied as a 30mg lyophilised vial. Reconstitution volume determines working concentration. Below are two common reconstitution approaches:
Option A: 3.0mL bacteriostatic water → 10mg/mL
| Dose | Volume at 10mg/mL | U100 Syringe Units |
|---|---|---|
| 2.5 mg | 0.25 mL | 25 units |
| 5 mg | 0.50 mL | 50 units |
| 7.5 mg | 0.75 mL | 75 units |
| 10 mg | 1.00 mL | 100 units |
| 12.5 mg | 1.25 mL | 125 units (use 0.5mL syringe twice) |
| 15 mg | 1.50 mL | 150 units (use 0.5mL syringe twice) |
Why not dilute further? A 30mg vial cannot be taken below 10mg/mL within a standard vial — reaching 5mg/mL would require 6.0mL of diluent, and most peptide vials hold only about 3mL. Option A is therefore the practical maximum dilution for a 30mg vial, and the resulting volumes (0.25mL at 2.5mg, 0.50mL at 5mg) are still readily measured on a U-100 insulin syringe.
For reconstitution technique (alcohol swab, angle of needle, swirl vs. roll), see the Peptide Reconstitution & Storage Guide. Reconstituted Tirzepatide should be stored refrigerated (2–8°C) and used within 28 days when reconstituted with bacteriostatic water.
Dual GLP-1/GIP Pharmacokinetics
Tirzepatide's pharmacokinetics differ from pure GLP-1 agonists in ways that are relevant to research protocol design. The compound is a synthetic 39-amino-acid peptide with a C20 fatty diacid modification enabling albumin binding and an extended half-life of approximately 5 days — shorter than Semaglutide's ~7 days but sufficient for once-weekly administration with consistent trough concentrations.
Key pharmacokinetic parameters from published data:
- Time to peak concentration (Tmax): 8–72 hours post-injection (per the FDA prescribing information)
- Steady-state: reached after 4–5 weeks of weekly dosing
- Half-life: approximately 5 days — see the molecular profile for the C20 acylation behind it
- Bioavailability (subcutaneous): approximately 80%
- GIP receptor activity: full agonism at physiological concentrations; GLP-1 receptor activity is partial agonism at lower doses, approaching full agonism at higher doses
The GIP receptor component contributes to adipose tissue and bone metabolism effects not seen with pure GLP-1 agonists. SURMOUNT-1 secondary endpoints showed improvements in waist circumference, fasting insulin, and HbA1c that exceeded predictions based on weight loss magnitude alone, consistent with direct GIP receptor activity in metabolic tissues.
Comparative Outcomes Across SURMOUNT Trials
The four completed SURMOUNT trials each addressed different research questions and populations, providing a comprehensive dataset for researchers studying Tirzepatide:
- SURMOUNT-1 (adults without T2D, 72 weeks): 15mg → −20.9% body weight; 10mg → −19.5%; 5mg → −15.0%
- SURMOUNT-2 (adults with T2D, 72 weeks): 15mg → −15.7%; confirmed efficacy in insulin-resistant population with attenuated but clinically significant effect
- SURMOUNT-3 (intensive lifestyle intervention lead-in, 72 weeks): participants who first lost ≥5% body weight via intensive lifestyle then randomised to Tirzepatide 15mg achieved a total mean loss of −26.6% from original baseline — the highest reported in any GLP-1 class trial to date
- SURMOUNT-4 (maintenance after initial weight loss on Tirzepatide): continuation vs. withdrawal at week 36 — continuation group reached −25.3% total loss; withdrawal group regained to −9.9% total loss at week 88, replicating the STEP 4 discontinuation pattern
For full SURMOUNT trial analysis, see the Tirzepatide SURMOUNT Trial Deep Dive. For comparison with Retatrutide and Semaglutide, see the Retatrutide vs Tirzepatide Research Comparison.
Injection Technique and Research Protocol Notes
Tirzepatide is administered via subcutaneous injection, identical in technique to Semaglutide. Approved injection sites in the SURMOUNT trials were the abdomen, thigh, and upper arm. Site rotation follows the same principles as other once-weekly peptide protocols — structured rotation across sites prevents localised lipohypertrophy and maintains consistent absorption kinetics.
For researchers designing protocols that reference the SURMOUNT escalation schedule, several practical notes from the trial methodology:
- Injection day consistency: weekly injection on the same day ±3 days is acceptable per SURMOUNT protocol; tighter consistency is preferable for pharmacokinetic studies
- Concomitant oral intake timing: Tirzepatide significantly delays gastric emptying — timing of oral compound administration relative to injection is relevant in multi-compound research designs
- Weight plateau recognition: SURMOUNT-1 weight loss curves show most participants reaching nadir between weeks 48–72; plateaus at maintenance dose are expected and are not indicative of tachyphylaxis
- Rebound kinetics: SURMOUNT-4 withdrawal data suggests weight regain begins within 4–8 weeks of cessation and follows a predictable trajectory — useful for designing washout periods in crossover study designs
All content is for laboratory research reference only. RetaLABS Tirzepatide is not for human consumption.